BrainsWay (NASDAQ:BWAY – Get Rating) had its price target trimmed by Raymond James from $8.00 to $3.75 in a research note released on Monday, Benzinga reports. The brokerage currently has an outperform rating on the stock.
Several other research firms have also recently weighed in on BWAY. Northland Securities lowered their price objective on BrainsWay from $15.00 to $5.00 and set an outperform rating on the stock in a research report on Thursday, November 17th. HC Wainwright raised their price objective on BrainsWay from $15.00 to $16.00 and gave the company a buy rating in a research note on Monday, August 22nd.
BrainsWay Stock Performance
Shares of BWAY opened at $1.99 on Monday. BrainsWay has a 52-week low of $1.90 and a 52-week high of $9.18. The stock has a 50 day simple moving average of $3.34 and a 200 day simple moving average of $4.72. The firm has a market capitalization of $32.87 million, a PE ratio of -6.22 and a beta of 1.42.
Institutional Inflows and Outflows
BrainsWay Company Profile
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on BrainsWay (BWAY)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.